EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY 4.0

Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?

Jose M Munita iD, Pranita D Tamma iD

Antimicrobial Agents and Chemotherapy · 02.04.2025 · 69 (4)

DOI: 10.1128/aac.00121-25 ↗

Kurz gefasst

Kommentar in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.04.2025. Verfasst von Jose M Munita und 1 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Acinetobacter Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem-resistant Acinetobacter baumannii (CRAB) remains a major threat, with high mortality and limited effective treatments. Sulbactam-durlobactam has emerged as a promising therapy against CRAB. Sulbactam-durlobactam was combined with imipenem-cilastatin in a clinical trial that led to its United States Food and Drug Administration approval. However, the additive benefit of imipenem remains uncertain. In a recent study (Antimicrob Agents Chemother 69:e01627-24, 2025, https://doi.org/10.1128/aac.01627-24 ), Veeraraghavan and colleagues provide convincing mechanistic evidence that adding imipenem to sulbactam-durlobactam enhances bacterial killing, likely through complementary inhibition of penicillin binding proteins, leveraging the concept of target redundancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAnti-Bacterial AgentsAcinetobacter InfectionsHumansImipenemSulbactamCarbapenemsDrug Resistance, Multiple, BacterialMicrobial Sensitivity Tests

Stichwörter der Autor:innen

Acinetobacter baumanniicarbapenem-resistantsulbactam-durlobactam

Substanzen

Anti-Bacterial AgentsImipenemSulbactamCarbapenems

Autor:innen und Institutionen

  • Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile.
  • Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Jose M Munita, Pranita D Tamma

Zitieren

APA

Munita, J. M., & Tamma, P. D. (2025). Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?. Antimicrobial Agents and Chemotherapy, 69(4). https://doi.org/10.1128/aac.00121-25

Vancouver

Munita JM, Tamma PD. Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?. Antimicrobial Agents and Chemotherapy. 2025;69(4). doi:10.1128/aac.00121-25

BibTeX
@article{Munita2025,
  author = {Munita, Jose M and Tamma, Pranita D},
  title = {Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {4},
  doi = {10.1128/aac.00121-25}
}
Kostenlos starten →